ICON Public Company (ICLR) Q4 2025 earnings summary

Executive summary

• Q4 and full-year 2025 results released alongside 2026 guidance and findings from an accounting investigation, which revealed improper revenue recognition adjustments from Q3 2023 to Q4 2024, overstating revenue by $65.3M in 2023 and $92.7M in 2024, but with no impact on cash flow or customer relationships.

• Material weaknesses in internal controls identified; comprehensive remediation plan underway.

• Commercial performance improved with a 19% year-over-year increase in net bookings and a book-to-bill ratio of 1.36x, with Q4 net business wins of $2,868M.

• Strategic focus on commercial excellence, automation, AI, and targeted investments in high-growth areas.

• $750M in share repurchases during the year.

Financial highlights

• Q4 2025 revenue: $2,113M, up 2.5% year-over-year and 1.3% sequentially; full-year 2025 revenue: $8,251M, up 0.8%.

• Adjusted EBITDA for Q4: $327.1M (15.5% margin); full-year adjusted EBITDA: $1,530.7M (18.6% margin), down 8.4% year-over-year.

• Adjusted EPS for Q4: $2.52 (vs. $3.86 in Q4 2024); full-year 2025: $12.53 (vs. $13.37 in 2024).

• Free cash flow for Q4: $174.8M; year-to-date: $862M.

• Net debt at year-end: $2.8B; leverage ratio: 1.8x net debt to adjusted trailing 12-month EBITDA.

Outlook and guidance

• 2026 revenue guidance: $7,850M–$8,150M; adjusted EPS: $10.00–$11.00.

• EBITDA margin expected to improve to ~16.5% for 2026, with sequential margin progression through the year.

• Revenue headwinds expected from prior booking environment and Symphony Health divestiture (2% impact).

• Pass-through revenue projected to remain flat year-over-year; direct fee revenue expected to decline.

• Margin improvement anticipated from efficiency gains, automation, and cost management.